u/Salt-Carpenter7873

Following my May review on GANX I posted on X, herewith a new update with a somewhat evolved template, before the 7th of October presentation. So, actually I'm a bit too early, before the full readout, but I believe there is high likelyhood of a share price rerating. Do your own dd. Bullish on $GANX

Full Article: https://x.com/benpieter001/status/2106720801940529164

happy reading!

note: this is my own research for my own portfolio. It suffers from all kinds of biases and convictions. written content is my own, but supported by ai agents for frequent bayesian scoring and report generation.

https://preview.redd.it/sdyug0fqrlth1.png?width=724&format=png&auto=webp&s=8e9d06bbce94a34730763a1c391c2dbbaed2c433

Following my May review of Gain Therapeutics on X (https://x.com/benpieter001/status/2106720801940529164), I’m sharing an updated report ahead of the October 7 congress presentation.

The thesis has evolved with the one-year clinical update, a broader expected biomarker package, and management’s discussions with potential partners. I’m particularly bullish on the fuller data that should report on sustained clinical stability with evidence (biomarkers) of an effect on the underlying disease biology.

Publishing before the presentation means some important questions remain open. Even so, I’m bullish on GANX: the gap between its current capitalization and the potential value of durable preservation in Parkinson’s looks substantial. Stronger clinical detail and a credible funding or partnership outcome could support a meaningful rerating.

Report attached. Happy reading, challenge the assumptions, and do your own due diligence.

GANX: updated research ahead of the October 7 presentation

GANX: updated research ahead of the October 7 presentation